Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

COUCH Medcomms

- PMLiVE

UK government announces nearly £50m to expand dementia research sites

The funding will be used to enable more people to take part in clinical trials for dementia

- PMLiVE

Roche and Exelis/Ipsen’s drug combination shows promise in phase 3 prostate cancer study

Around 299,000 new cases of prostate cancer will be diagnosed in the US in 2024

- PMLiVE

Michael J Fox Foundation awards Vesper Bio over $870,000 for Parkinson’s treatment

Vesper is currently developing VES001 for GRN-mutated frontotemporal dementia

- PMLiVE

Mental health – from research to remission

Barriers, opportunities and the need for pioneering progress in depression

Engaging with Different Perspectives – Top 10 Most Important Advisor Questions

In this quick clip, we highlight a vital tip from our 'Top 10 Most Important Advisor Questions' – essential for enhancing your virtual collaboration strategies in Pharma and Life Sciences....

Impetus Digital

Health literacy icons in Cuttsy+Cuttsy branded shapes

Clinical trials explained: Why health literacy matters…

Clinical trial recruitment can be a challenge. By applying the principles of health literacy to all materials, we can support people to make an informed choice about whether to take...

Cuttsy + Cuttsy

- PMLiVE

Roche’s Genentech and GenEdit enter autoimmune disease partnership worth up to $644m

The companies will develop nanoparticles to deliver genetic medicines for autoimmune diseases

- PMLiVE

Ionis shares positive phase 3 results for hereditary angioedema drug candidate

More than 20,000 people in the US and Europe are affected by the rare genetic disease

- PMLiVE

NICE recommends two AI-powered software tools for stroke diagnosis in NHS

Brainomix's e-Stroke and Ischemaview’s RapidAI were reported by the health technology assessment agency to improve access to treatment for stroke patients

- PMLiVE

ACCORD: new guideline to support consistent and complete reporting of consensus methods in biomedical research

Oxford PharmaGenesis has contributed to the development of the new ACCORD reporting guideline to help the medical and scientific communities to improve the reporting of research involving consensus methodologies.

Oxford PharmaGenesis

- PMLiVE

March-in rights explained

Maybe... kind of... It’s all very confusing actually

- PMLiVE

LEO shares positive results for delgocitinib cream in head-to-head chronic hand eczema study

Hand eczema is the most common skin disorder of the hands and one of the most common eczemas

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links